Bioventus (BVS) AI Stock Analysis

• Market Cap: $716.79M
• Dividend Yield: N/A
• Average Volume (3M): 257.41K
• Price to Earnings (P/E): 21.8
• Beta (1Y): 0.92
• Revenue Growth: 1.58%
• EPS Growth: N/A
• Country: US
• Employees: 930
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.24
• Shares Outstanding: 67,368,050
• 10 Day Avg. Volume: 219,442
• 30 Day Avg. Volume: 257,406
• PEG Ratio: -0.13
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 6.94
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 1.48
• Enterprise Value/Gross Profit: 2.17
• Enterprise Value/Ebitda: 7.97
• 1Y Price Target: $15.00
• Price Target Upside: 74.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.77
• Revenue Forecast (FY): $604.18M

• Rating: 65 Neutral
• Price Target: $10.00 ▲(16.01% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is driven primarily by improving financial performance (profitability rebound and strong free cash flow) and supportive technical momentum (price above key moving averages). Offsetting factors are a still-risky balance sheet history/leverage sensitivity and only moderate valuation support (P/E ~21.8 with no dividend), while earnings call guidance and deleveraging targets provide a constructive but not risk-free outlook given near-term headwinds.

Positive Factors

Cash generation

Sustained high operating and free cash flow provides durable internal funding for R&D, product commercialization, and debt reduction. Free cash flow roughly tracking net income and record quarterly cash from operations improve financial flexibility and reduce reliance on external financing over the medium term.

Margin expansion

Material gross- and EBITDA-margin expansion reflects favorable product mix, pricing power and operational leverage. Management targets ~20% adjusted EBITDA, which, if sustained, supports persistent cash generation, funds reinvestment in growth initiatives and strengthens resilience to revenue cyclicality.

New product growth drivers

Successful PNS and PRP pilots and committed investment create durable revenue diversification and higher-growth adjacencies. If physician adoption scales, these products can drive sustained above-market organic growth, improve unit economics, and expand addressable markets over the next several years.

Negative Factors

Historical leverage

A recent history of high leverage constrains financial flexibility and raises interest-expense sensitivity to rate moves. While debt levels have declined and management targets further deleveraging, lingering leverage increases vulnerability to operational setbacks and limits capital allocation options if cash flow weakens.

Thin, volatile net profitability

Despite strong revenue growth and healthy gross margins, net profitability remains thin and historically volatile due to prior losses and non‑operating costs. Low net margins reduce the buffer for funding investments or absorbing shocks and heighten the impact of any margin or volume setbacks on earnings sustainability.

FX and distributor exposure

Meaningful currency exposure and reliance on distributor ordering patterns create structural revenue volatility across reporting periods. Persistent FX swings and inventory rebalancing by channel partners can erode reported growth and complicate forecasting, making medium-term top-line visibility and execution riskier.

Bioventus Business Overview & Revenue Model

Company Description

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Bioventus generates revenue through multiple streams, primarily from the sale of its medical devices, biologic products, and therapeutic solutions. The company has a strong focus on the orthopedic market, where it markets its ultrasound devices and other technologies to hospitals, clinics, and outpatient facilities. Significant partnerships with healthcare providers and distributors enhance its market reach and facilitate sales. Additionally, Bioventus may also derive income from research collaborations, licensing agreements, and product development partnerships, which further diversify its revenue sources. The company's commitment to innovation and its pipeline of new products are crucial factors contributing to its earnings potential.

Bioventus Financial Statement Overview

Summary

TTM shows a meaningful turnaround with strong revenue growth (+75.5%), healthy gross margin (~67.5%), positive EBIT ($54.8M), and solid free cash flow ($72.1M). Offsetting this, net margin remains thin (~1.4%) and the balance sheet has a recent history of elevated leverage (debt-to-equity >~2x in 2023–2024) with only modest debt coverage from operating cash flow (~0.35).

Income Statement

TTM (Trailing-Twelve-Months) results show a clear profitability rebound with positive EBIT ($54.8M) and net income ($22.7M) after losses in 2024 and 2023. Revenue growth is strong in TTM (+75.5%), and gross margin remains healthy (~67.5%). However, bottom-line profitability is still relatively thin versus the revenue base (net margin ~1.4%), and the multi-year record shows meaningful earnings volatility (large net losses in 2022–2023), which tempers the score.

Balance Sheet

Leverage has been a major constraint historically (debt-to-equity above ~2x in 2023–2024), and returns on equity were deeply negative during the loss years. TTM shows improvement in profitability (positive return on equity ~5%), and reported total debt is much lower in TTM versus prior annual periods, which would be a material de-risking if sustained. Still, given the recent history of elevated leverage and earnings pressure, the balance sheet profile remains a key risk area.

Cash Flow

Cash generation is a relative strength: TTM operating cash flow is solid ($74.7M) and free cash flow is strong ($72.1M) with sizable growth. Cash flow quality also looks good with free cash flow roughly in line with net income (free cash flow to net income ~0.95). The main weakness is that operating cash flow covers only a modest portion of debt in TTM (coverage ~0.35), and coverage was even lower in prior years, implying leverage can still pressure financial flexibility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	568.09M	573.28M	512.35M	512.12M	430.90M
Gross Profit	382.43M	388.23M	328.19M	331.08M	302.71M
EBITDA	105.56M	39.22M	-23.07M	-121.61M	45.48M
Net Income	22.73M	-33.54M	-156.23M	-158.70M	19.38M
Balance Sheet
Total Assets	683.56M	727.96M	810.91M	1.37B	1.23B
Cash, Cash Equivalents and Short-Term Investments	51.24M	41.58M	36.96M	30.19M	43.93M
Total Debt	311.35M	335.63M	394.85M	418.07M	357.68M
Total Liabilities	455.11M	542.35M	589.79M	960.43M	692.07M
Stockholders Equity	184.10M	147.94M	173.59M	325.24M	458.92M
Cash Flow
Free Cash Flow	71.41M	37.79M	7.98M	-15.02M	2.10M
Operating Cash Flow	73.98M	38.80M	15.34M	-13.54M	22.99M
Investing Cash Flow	-3.25M	22.96M	15.81M	-116.44M	-283.76M
Financing Cash Flow	-61.44M	-54.58M	-26.65M	62.08M	273.37M

Bioventus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Positive. The current price of 8.62 is below the 20-day moving average (MA) of 8.66, above the 50-day MA of 8.22, and above the 200-day MA of 7.30, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 42.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BVS.

Bioventus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	65 Neutral	$716.79M	21.81	4.97%	―	1.58%	―
SIBN	56 Neutral	$576.36M	-45.38	-12.91%	―	23.27%	43.90%
KIDS	55 Neutral	$437.58M	-10.51	-12.67%	―	19.90%	-57.90%
VREX	52 Neutral	$452.94M	52.93	-13.95%	―	4.14%	-45.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	50 Neutral	$469.69M	-6.56	-20.38%	―	4.31%	3.26%